Loading...
•
Dec 31, 2024
Acasti Pharma Q3 2025 Earnings Report
Grace Therapeutics reported results for the third fiscal quarter of 2025, announcing positive topline data from the Phase 3 STRIVE-ON safety trial and securing up to $30 million in gross proceeds from a private placement financing.
Key Takeaways
Grace Therapeutics reported a net loss of $4.2 million, or $0.36 per share, for the quarter ended December 31, 2024. The company announced positive topline data from its Phase 3 STRIVE-ON safety trial and secured up to $30 million in gross proceeds from a private placement financing.
Phase 3 STRIVE-ON safety trial met primary endpoint, demonstrating clinical benefit compared to orally administered nimodipine.
NDA submission to the FDA is anticipated in the first half of calendar year 2025 for GTx-104.
Secured private placement financing of up to approximately $30.0 million in potential total gross proceeds.
Received written responses to its End of Phase 1 meeting in GTx-102 where the FDA made recommendations on the path toward an NDA.
Forward Guidance
Grace Therapeutics focuses on finalizing NDA submission for GTx-104 by the end of June 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...